Oral Magnesium Supplementation Improved Lipid Profile but Increased Insulin Resistance in Patients with Diabetic Nephropathy: a Double-Blind Randomized Controlled Clinical Trial
Sadeghian M, Azadbakht L, Khalili N, Mortazavi M, Esmaillzadeh A
Biological trace element research · 24 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- Isfahan University of Medical Sciences
- Subvenciones
- Isfahan University of Medical Sciences (193012)
Según 1 financiador declarado.
Publicación
- Publicado
- 2019-03-05 · Biol Trace Elem Res · vol. 193 · número 1 · págs. 23–35
- Editorial
- Springer Science+Business Media
- Citado
- 36 citas · más que el 91% de estudios similares · 3.1× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 40 trabajos
- Acceso
- De pago
- Áreas de investigación
- Magnesium in Health and Disease · Chronic Kidney Disease and Diabetes · Magnesium Oxide Properties and Applications
- Palabras clave
- magnesium supplementation, magnesium oxide, diabetic nephropathy, insulin resistance, lipid profile, type 2 diabetes, hypomagnesemia, microalbuminuria, renal function, serum cholesterol, triglycerides, inflammation
- MeSH
- humans, diabetic nephropathies, albuminuria, insulin resistance, inflammation, magnesium, magnesium oxide, creatinine, lipids, administration, oral, double-blind method, adult, middle aged, female, male
5 autores
- Mehdi Sadeghian🇮🇷Isfahan University of Medical Sciences
- Leila Azadbakht🇮🇷Isfahan University of Medical Sciences; Tehran University of Medical Sciences
- Noushin Khalili🇮🇷Isfahan University of Medical Sciences
- Mojgan Mortazavi🇮🇷Isfahan University of Medical Sciences
- Ahmad Esmaillzadeh🇮🇷 · autor de correspondenciaIsfahan University of Medical Sciences; Tehran University of Medical Sciences
Resumen
El texto original del estudio, en el idioma en que se publicó.
Low serum magnesium concentrations were associated with development of renal failure. We aimed to determine whether magnesium supplementation improves renal function, insulin resistance, and metabolic profiles in patients with diabetic nephropathy. A total of 80 hypomagnesemic patients diagnosed with type 2 diabetes and early-stage nephropathy were recruited. Subjects received either daily magnesium oxide or placebo for 12 weeks. Biochemical and anthropometric variables were measured. Physical activity and dietary intakes were also recorded. This study was approved by the ethics committee of Isfahan University of Medical Sciences and was registered on the Iranian Registry of Clinical Trials website (IRCT registration no. IRCT201404271485N12). Serum magnesium levels were not changed significantly. Although the supplementation did not influence glycemic indices, patients in the magnesium group had greater insulin resistance compared with the placebo group after intervention (0.3 ± 2.3 μIU/mL vs. - 0.04 ± 2.05, P = 0.04). No significant changes were observed in serum total cholesterol, triglycerides, HDL, LDL, and total cholesterol/HDL cholesterol ratio. Furthermore, magnesium did not affect inflammation, serum levels of creatinine, and blood urine nitrogen. However, a marginal decrease in microalbuminuria (- 3.1 ± 2.2 mg/L vs. - 14 ± 9.9, P = 0.09) was observed. Oral magnesium supplementation slightly improved microalbuminuria but resulted in increased insulin resistance in patients with diabetic nephropathy.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.